Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers.
OBJECTIVE
The chromosomal radiosensitivity of a selected group of familial breast cancer patients carrying a mutation in BRCA1 (n=11) or BRCA2 (n=9) and a group of healthy mutation carriers (n=12) was investigated and compared to a reference group of breast cancer patients without a BRCA1/2 mutation (n=78) and a group of healthy women carrying no mutation (n=58).


METHODS
The chromosomal radiosensitivity was assessed with the G2 and the G0-micronucleus (MN)-assay on fresh blood samples and on Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines. For the MN-assay, lymphocytes were exposed in vitro to 3.5 Gy and 2 Gy 60Co gamma-rays at a high dose rate (HDR) or low dose rate (LDR). 70-h post-irradiation cultures were arrested and micronuclei were scored in 1000 binucleate cells. For the G2-assay lymphocytes were irradiated in vitro with a dose of 0.4 Gy 60Co gamma-rays after 71h incubation. Cultures were arrested 90 min after irradiation and chromatid breaks were scored in 50 metaphases.


RESULTS
The group of breast cancer patients with a BRCA1 or 2 mutation was on average more radiosensitive than the control group, but not different from breast cancer patients without a BRCA mutation. The radiation response of healthy BRCA1/2 carriers was not significantly different from the control group and also not different from relatives without a BRCA mutation. Comparing the radiation response in EBV cell lines derived from breast cancer patients with or without a BRCA1 mutation revealed no significant difference.


CONCLUSIONS
Our results reveal that chromosomal radiosensitivity observed in breast cancer patients heterozygous for BRCA1 or 2 mutations, could not be demonstrated in healthy BRCA1/2 mutation carriers. This suggests that mutations in BRCA1 or 2 genes are not playing a main role in chromosomal radiosensitivity, this although BRCA1 and 2 are both involved in DNA repair/signalling processes.
Baeyens
A
A
Department of Anatomy, Embryology, Histology and Medical Physics, Ghent University, L. Pasteurlaan 2, B-9000 Gent, Belgium.
Thierens
H
H
Claes
K
K
Poppe
B
B
de Ridder
L
L
Vral
A
A
D019313:BRCA1 Protein / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D024682:BRCA2 Protein / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics / Q000532:radiotherapy; D002478:Cells, Cultured; D019457:Chromosome Breakage / Q000235:genetics; D002875:Chromosomes / Q000528:radiation effects*; D004307:Dose-Response Relationship, Radiation; D020031:Epstein-Barr Virus Infections / Q000235:genetics / Q000378:metabolism; D005260:Female; D005720:Gamma Rays / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism / Q000528:radiation effects*; D015162:Micronucleus Tests / Q000379:methods; D009154:Mutation; D011836:Radiation Tolerance; D013997:Time Factors
D019313:BRCA1 Protein; D024682:BRCA2 Protein